Advertisement

Advances in Therapy

, Volume 25, Issue 9, pp 842–857 | Cite as

Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review

  • Scott W. K. SiegertEmail author
  • Robert J. Holt
Review

Abstract

Introduction

Intravenous (i.v.) hematin has been used in the treatment of acute intermittent porphyria (AIP) since the early 1970s and commercially available as Panhematin® (hemin for injection; Ovation Pharmaceuticals, Inc., USA) since 1983, yet no publication to date has attempted to summarize the known pharmacodynamics and toxicological actions of hematin and the implications on treatment. It is the objective of this literature review to identify, consolidate, and summarize the available scientific literature regarding the physicochemical properties, pharmacokinetics, toxicology, and hemostatic effects of i.v. hematin injections.

Methods

A comprehensive search of the available literature was performed and resulting data were summarized. Furthermore, previously unpublished toxicology data extracted from the original New Drug Application were included.

Results

Hematin, reconstituted with sterile water, rapidly degrades and it is hypothesized that the degradation products lead to morbidities such as thrombophlebitis, thrombocytopenia, and transient anticoagulation. Reconstitution with human serum albumin produces a well-tolerated hematin preparation and improves its stability significantly. The clearance of i.v. hematin infusions are shown to fit a two-compartment model consisting of a rapid initial rate followed by a slower and prolonged second phase. This model is supported by the evidence demonstrating that hematin is first bound by hemopexin and, upon saturation, second by albumin. The highest i.v. human hematin dose reported in the literature was 12.2 mg/kg (1000 mg) and resulted in acute gastrointestinal pain, paresthesia, and acute tubercular necrosis. The patient’s renal function returned to normal over the following 15 hours.

Conclusion

Hematin, at doses approved by the US Food and Drug Administration, is generally well tolerated. Reconstitution with albumin produces a significantly more stable preparation than reconstitution with sterile water and may lead to a more tolerable administration with less hemostatic interference. Hematin, once administered, is cleared hepatically and is best represented pharmacokinetically by a two-compartment model comprised of a rapid initial phase followed by a slower second phase.

Keywords

intravenous hematin Panhematin pharmacokinetics porphyria toxicology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Panhematin (hemin for injection) package insert. Deerfield, IL: Ovation Pharmaceuticals, Inc., USA; August 2006.Google Scholar
  2. 2.
    Pierach CA. Hematin therapy for the porphyric attack. Semin Liver Dis. 1982;2:125–131.PubMedCrossRefGoogle Scholar
  3. 3.
    Lamon JM, Frykholm BC, Hess RA, Tschudy DP. Hematin therapy for acute porphyria. Medicine. 1979;58:252–269.PubMedCrossRefGoogle Scholar
  4. 4.
    Mustajoki P, Tenhunen R, Pierach C, Volin L. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol. 1989;26:1–9.PubMedGoogle Scholar
  5. 5.
    Dhar G, Bossenmaier I, Petryka Z, Cardinal R, Watson C. Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med. 1975;83:20–30.PubMedGoogle Scholar
  6. 6.
    Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991;86:1050–1056.PubMedGoogle Scholar
  7. 7.
    Chung WY, Lee JM, Lee WY, Surh YJ, Park KK. Protective effects of hemin and tetrakis(4-benzoic acid)porphyrin on bacterial mutagenesis and mouse skin carcinogenesis induced by 7, 12-dimethylbenz[a]anthracene. Mutat Res. 2000;472:139–145.PubMedGoogle Scholar
  8. 8.
    Park KK, Park JH, Jung YJ, Chung WY. Inhibitory effects of chlorophyllin, hemin and tetrakis(4-benzoic acid) porphyrin on oxidative DNA damage and mouse skin inflammation induced by 12-O-tetradecanoylphorbol-13-acetate as a possible anti-tumor promoting mechanism. Mutat Res. 2003;542:89–97.PubMedGoogle Scholar
  9. 9.
    Al-Waili NS, Butler GJ. Phototherapy and malignancy: possible enhancement by iron administration and hyperbaric oxygen. Med Hypotheses. 2006;67:1148–1158.PubMedCrossRefGoogle Scholar
  10. 10.
    Kneidinger M, Gleixner K, Kondo R, et al. Heme oxygenase-1 (HO-1) / heat shock protein 32 (Hsp32) as a novel survival factor and target in AML. Poster presented at: Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida.Google Scholar
  11. 11.
    Sato H, Siow RC, Bartlett S, et al. Expression of stress proteins heme oxygenase-1 and-2 in acute pancreatitis and pancreatic islet betaTC3 and acinar AR42J cells. FEBS Lett. 1997;405:219–223.PubMedCrossRefGoogle Scholar
  12. 12.
    Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, Omary MB. Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction. J Clin Invest. 2005;115:3007–3014.PubMedCrossRefGoogle Scholar
  13. 13.
    Ruutu T, Volin L, Tenhunen R. Haem arginate as a treatment for myelodysplastic syndromes. Br J Haematol. 1987;65: 425–428.PubMedCrossRefGoogle Scholar
  14. 14.
    Volin L, Ruutu T, Knuutila S, Tenhunen R. Heme arginate treatment for myelodysplastic syndromes. Leuk Res. 1988;12:423–431.PubMedCrossRefGoogle Scholar
  15. 15.
    Timonen TT, Kauma H. Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur J Haematol. 1992;49: 234–238.PubMedCrossRefGoogle Scholar
  16. 16.
    Rochant H, Fenaux P, Guerci A, et al. Results of heme arginate treatment of myelodysplastic syndromes. A multicenter phase II study of the French group of myelodysplastic syndromes. Blood. 1996;88(suppl. 1):210b:3566.Google Scholar
  17. 17.
    Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J Immunol. 2006;176:4252–4257.PubMedGoogle Scholar
  18. 18.
    Levere RD, Gong Y, Kappas A, et al. Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine. Proc Natl Acad Sci U S A. 1991;88:1756–1759.PubMedCrossRefGoogle Scholar
  19. 19.
    Staudinger R, Abraham NG, Levere RD, Kappas A. Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs. Proc Assoc Am Physicians. 1996;108:47–54.PubMedGoogle Scholar
  20. 20.
    Chen Y, Zhu X, Zhao X, Xing H, Li Y. Hemin, a heme oxygenase-1 inducer, improves aortic endothelial dysfunction in insulin resistant rats. Chin Med J. 2008;121:241–247.PubMedGoogle Scholar
  21. 21.
    Fischer H, Orth H. Die Chemie des Pyrrols. B II. I. Halfte. Akademische Verlagsgesellschaft. Leipzig;1937:37–38.Google Scholar
  22. 22.
    Simionatto C, Cabal R, Jones R, Galbraith R. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am J Med. 1988;85:538–540.PubMedCrossRefGoogle Scholar
  23. 23.
    Goetsch C, Bissell D. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235–238.PubMedGoogle Scholar
  24. 24.
    Morris D, Dudley M, Pearson R. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med. 1981;95:700–701.PubMedGoogle Scholar
  25. 25.
    Glueck R, Green D, Cohen I, Ts’ao C. Hematin: unique effects of hemostasis. Blood. 1983;61:243–249.PubMedGoogle Scholar
  26. 26.
    Green D, Reynolds N, Klein J, Kohl H, Ts’ao C. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361–369.PubMedGoogle Scholar
  27. 27.
    Jones R. Hematin-derived anticoagulant: generation in vitro and in vivo. J Exp Med. 1986;163:724–739.PubMedCrossRefGoogle Scholar
  28. 28.
    Cannon J, Yunker M, Luoma N. The effect of aggregation inhibitors and antioxidants on the stability of hemin solutions. PDA J Pharm Sci Technol. 1995;49:77–82.PubMedGoogle Scholar
  29. 29.
    Cannon J. Pharmaceutics and drug delivery aspects of heme and porphyrin therapy. J Pharm Sci. 1993;82:435–446.PubMedCrossRefGoogle Scholar
  30. 30.
    Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60:79–127.PubMedCrossRefGoogle Scholar
  31. 31.
    Smith A, Morgan W. Hemopexin-mediated heme uptake by liver: characterization of the interaction of heme-hemopexin with isolated rabbit liver plasma membranes. J Biol Chem. 1984;259:12049–12053.PubMedGoogle Scholar
  32. 32.
    Noyer C, Immenschuh S, Liem H, Muller-Eberhard U, Wolkoff A. Initial heme uptake from albumin by short-term cultured rat hepatocytes is mediated by a transport mechanism differing from that of other organic anions. Hepatology. 1998;29: 150–155.CrossRefGoogle Scholar
  33. 33.
    Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta. 2001;312:13–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Sears D, Huser H. Plasma hematin-binding and clearance in the rhesus monkey. Proc Soc Exp Biol Med. 1966;121:11–16.Google Scholar
  35. 35.
    Petryka Z, Dhar G, Bossenmaier I. Hematin clearance in porphyria. Conference proceedings. 1st International Porphyrin Meeting, 1975. Basel: Karger; 1976: 259–256.Google Scholar
  36. 36.
    Ovation data on file. Safety test for Panhematin® (hemin for injection). Ovation Pharmaceuticals, Inc., Illinois, USA.Google Scholar
  37. 37.
    Lips D, Pierach C, Edwards P. Hematin toxicity in rats. Toxicol Lett. 1978;2: 329–332.CrossRefGoogle Scholar
  38. 38.
    Anderson W, Morrison D, Williams E. Pathologic changes following injections of ferrihemate (hematin) in dogs. Arch Pathol. 1942;33:589–602.Google Scholar
  39. 39.
    Waters L, Roberts R. Effect of several endogenous substances-including porphyrins, hematin, and carbon monoxideon hepatic clearance of sulfobromphthalein. Toxicol Lett. 1974;2:223–229.Google Scholar
  40. 40.
    Corcoran A, Page I. Renal damage from ferroheme pigments myoglobin, hemoglobin, hematin. Tex Rep Biol Med. 1945;3:528–544.Google Scholar
  41. 41.
    Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203: 437–443.PubMedGoogle Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  1. 1.University of Illinois at Chicago College of PharmacyIllinoisUSA
  2. 2.Medical InformationOvation Pharmaceuticals, Inc.IllinoisUSA
  3. 3.Medical AffairsOvation Pharmaceuticals, Inc.IllinoisUSA

Personalised recommendations